
Genetic Testing Company Invitae’s Stock Slides as Losses Mount
Genetic testing company Invitae’s (NVTA) stock has been a poor investment this year as its dropped from $42 to $17.

Genetic testing company Invitae’s (NVTA) stock has been a poor investment this year as its dropped from $42 to $17.

Invitae (NVTA) was a $50 stock. Now its around $30, But NVTA has ~50% upside as revenue is expected to grow ~50% long-term.

Invitae (NVTA) is a leader in Genetic testing. But stoks like this are totally out of favor right now. But the future is bright.

Invitae (NVTA) is a leader in comprehensive cancer genetics and precision oncology, doing $100 million in revenue per qtr.

Invitae (NVTA) is expected to have some HUGE revenue increases in the upcoming years as genetic testing increases.

Little DNA testing company Invitae (NVTA) could be a stock market winner as the genetic testing industry evolves.

Invitae (NVTA) continues to climb after its merger with ArcherDX makes the company a leader in cancer testing.
Invitae (NVTA) reports earnings:
Invitae (NVTA) reports earnings:
Invitae (NVTA) reports earnings: